- Record: found
- Abstract: not found
- Article: not found
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial
Aditya H Gaur ,
James S McCarthy ,
John C Panetta ,
Ronald H Dallas ,
John Woodford ,
Li Tang ,
Amber M Smith ,
Tracy B Stewart ,
Kristen C Branum ,
Burgess B Freeman ,
Nehali D Patel ,
Elizabeth John ,
Stephan Chalon ,
Shelley Ost ,
Ryan N Heine ,
Julie L Richardson ,
Robbin Christensen ,
Patricia M Flynn ,
Yvonne Van Gessel ,
Branko Mitasev ,
Jörg J Möhrle ,
Fabian Gusovsky ,
Lidiya Bebrevska ,
R Kiplin Guy
April 2020
April 2020
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d35639068e315">(+)-SJ000557733 (SJ733) is a novel, orally bioavailable
inhibitor of Plasmodium falciparum
ATP4. In this first-in-human and induced blood-stage malaria phase 1a/b trial, we
investigated the safety, tolerability, pharmacokinetics, and antimalarial activity
of SJ733 in humans.
</p>